Exact, GE Healthcare to develop ACT ultrasound probe

By AuntMinnie.com staff writers

January 20, 2021 -- Exact Therapeutics and GE Healthcare are developing an ultrasound probe that will be used to test acoustic cluster therapy (ACT) for multiple diseases in upcoming studies.

ACT is a proprietary formula that consists of microbubbles and microdroplets that are activated via ultrasound to increase the targeted delivery of a co-administered therapeutic agent. Preclinical data have shown that it enhances treatment for pancreatic, breast, colon, and prostate cancer, as well as managing blood-brain barrier opening.

The therapy is being evaluated in patients with metastatic colorectal and pancreatic cancer in a phase I trial at the Royal Marsden Hospital in London.

Copyright © 2021 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking